Evidence map›Paper›PMID 31366908›Full record

ArticleNature communications2019

The LipoGlo reporter system for sensitive and specific monitoring of atherogenic lipoproteins.

James H Thierer, Stephen C Ekker, Steven A Farber

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Zebrafish ApoB-Containing Lipoprotein Metabolism: A Closer Look.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

James H ThiererCarnegie Institution for Science Department of Embryology, 3520 San Martin Drive, Baltimore, MD, 21218, USA.ORCID http://orcid.org/0000-0002-1679-2255
Stephen C EkkerDepartment of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0003-0726-4212
Steven A FarberCarnegie Institution for Science Department of Embryology, 3520 San Martin Drive, Baltimore, MD, 21218, USA. Farber@Carnegiescience.edu.ORCID http://orcid.org/0000-0002-8037-7312
Johns Hopkins University · USMayo Clinic · US

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
CELLULAR AND MOLECULAR BIOLOGYT32GM007231 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI VAN DOREN, MARK B · 1985 to 2020
$18.4M
Systematic Vertebrate Functional GenomicsR01GM063904 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI EKKER, STEPHEN CARL · 2001 to 2025
$10.7M
Identifying genes required for digestive physiology and lipid metabolismR01DK093399 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI STEVEN A FARBER, John F Rawls · 2013 to 2026
$7.6M
Cellular and Molecular BiologyT32GM141804 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI John Kim · 2021 to 2026
$5.1M
In vivo HTS assay for novel modulators of Apolipoprotien BR01DK116079 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI FARBER, STEVEN A · 2018 to 2022
$3.2M
Acquisition of GE Typhoon FLA9500 Variable Mode ImagerS10OD021567 · OD · JOHNS HOPKINS UNIVERSITY · PI MCCAFFERY, J. MICHAEL · 2017 to 2017
$147k
Discovery and characterization of novel regulators of Apo-B in larval zebrafishF31HL139338 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI THIERER, JAMES HENRY · 2017 to 2018
$89k
NHLBI NIH HHS F31 HL139338NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK093399NIDDK NIH HHS R01 DK116079NIGMS NIH HHS R01 GM063904NIGMS NIH HHS T32 GM007231NIGMS NIH HHS T32 GM141804NIH HHS S10 OD021567
6 · The paper itself

Abstract

Apolipoprotein-B (ApoB) is the structural component of atherogenic lipoproteins, lipid-rich particles that drive atherosclerosis by accumulating in the vascular wall. As atherosclerotic cardiovascular disease is the leading cause of death worldwide, there is an urgent need to develop new strategies to prevent lipoproteins from causing vascular damage. Here we report the LipoGlo system, which uses a luciferase enzyme (NanoLuc) fused to ApoB to monitor several key determinants of lipoprotein atherogenicity including particle abundance, size, and localization. Using LipoGlo, we comprehensively characterize the lipoprotein profile of individual larval zebrafish and collect images of atherogenic lipoprotein localization in an intact organism. We report multiple extravascular lipoprotein localization patterns, as well as identify Pla2g12b as a potent regulator of lipoprotein size. ApoB-fusion proteins thus represent a sensitive and specific approach to study atherogenic lipoproteins and their genetic and small molecule modifiers.

Indexed as

AnimalsApolipoproteins BAtherosclerosisHumansLarvaLipoproteins, LDLLuciferasesPhospholipases A2Staining and LabelingZebrafishZebrafish ProteinsApolipoproteins BLipoproteins, LDLLuciferasesPhospholipases A2pla2g12b protein, zebrafishZebrafish Proteins

Identifiers

PMID31366908
PMCPMC6668417
OpenAlexW2965510852

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.